WESTBOROUGH, Mass., June 20 /PRNewswire/ -- IBC Life Sciences today announced that the R&D Strategies and Business Alliances Conference, one of the six conferences to be held at the Drug Discovery Technology(R) and Development World Congress, has been expanded to three full days of presentations and panel discussions. More than 50 industry leaders from large to small pharma, biologics to biotechnology companies, VCs to corporate venture funds, will gather to discuss and debate over 3 days from August 8-10, 2006 in Boston, Massachusetts.
The new agenda features R&D panel discussions covering strategies on cost optimization, improvement on innovation, new models in R&D, the role of Asia and Eastern Europe, efficient management of outsourcing relationship and conducting of international clinical trials. In addition case studies on creative deals will be covered, including AstraZeneca-Atherogenics, KAI-Sankyo, and the new business model of DMO corporations.
The Early Stage Company Showcase will return this year on Thursday, August 10, with 15 emerging companies and technologies, in front of the critique panel who will provide constructive suggestions on soundness of business model and novelty of technology or services provided.
As part of the 2006 Drug Discovery Technology(R) & Development World Congress, all attendees have access to the four keynote presentations from: Andrew C. von Eschenbach, M.D., Acting Commissioner, FDA and Director, National Cancer Institute, Steven M. Paul, M.D., Executive Vice President, Science and Technology, President, Lilly Research Laboratories, Eli Lilly and Company, Peter B. Corr, Ph.D., Senior Vice President, Science & Technology, Pfizer Inc and Susan Hockfield, Ph.D., President, Massachusetts Institute of Technology. Attendees also have option to register for any of the seven half-day, pre-conference workshops on Monday, August 7.
The World Congress expects more than 4,000 pharmaceutical, biotechnology, government and academic researchers, executives and technology providers to participate. The conference will provide more coverage of the most vital topics in drug discovery and development. This year’s conference includes more speakers, case studies, panel discussions, keynotes, chemistry-focused sessions and R&D strategy & business sessions in six focused conferences.
Complete details on this event can be found at http://www.drugdisc.com/us or to receive a press pass or arrange an interview with a speaker, email Dawn Eagan at deagan@ibcusa.com.
About Drug Discovery Technology(R) & Development World Congress
Drug Discovery Technology(R) & Development World Congress (DDT), now in its 11th year, is the industry’s premier, international conference and exhibition to provide education on the most vital topics in drug discovery and development to help accelerate products to market. The event provides a meeting place for attendees from around the world to network, find business and scientific partners and to discuss scientific advances, R&D strategies, business alliances and informatics solutions in drug discovery and development.
About IBC Life Sciences
IBC Life Sciences is the worldwide leader in scientific, technological and business conferences and courses for the life science industry. To develop its programs, IBC actively researches the advancements, technologies and trends impacting and driving the race for new drugs and therapies. No other organization can make claim to the breadth and quality that IBC Life Sciences delivers in each event giving the company recognition around the globe for quality, service and value. For more information, visit: http://www.IBCLifeSciences.com.
Contact: Dawn Eagan IBC Life Sciences 508-614-1679 deagan@ibcusa.com
IBC Life Sciences
CONTACT: Dawn Eagan of IBC Life Sciences, +1-508-614-1679,deagan@ibcusa.com
Web site: http://www.lifesciencesinfo.com//
